Home
Clinical Trials
Serum Neurofilament-light Cha...

Serum Neurofilament-light Chain and GFAP Levels in Patients From the OFSEP Cohort at Different Landmarks of Multiple Sclerosis

Last Updated: 2024-05-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

1150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-05-22

Study Completion Date

2028-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators hypothesize that serum neurofilament-light chain (NfL) levels can provide information about the level of activity and progression of Multiple Sclerosis at different stages and landmarks of the disease.

In addition, Glial Fibrillary Acidic Protein (GFAP) has also been identified as another serum biomarker of disability in MS.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Assessment of NfL and GFAP Levels, Atrophy of the Macula GCC by OCT and Whole Brain Atrophy by MRI to Predict Evolution of Neurological Disability in MS Patients

NCT04860947

Multiple Sclerosis

ACTIVE_NOT_RECRUITING

Validation of Ella Platform for Serum Nfl And GFAP Measures In Multiple Sclerosis Patients

NCT05352971

Multiple Sclerosis

COMPLETED

Serum Neurofilament Light in Multiple Sclerosis

NCT06282081

Multiple Sclerosis Relapsing Remitting Multiple Sclerosis

ACTIVE_NOT_RECRUITING

Serum Neurofilaments and GFAP in Atypical Multiple Sclerosis

NCT04201470

Relapsing Remitting Multiple Sclerosis Progressive Multiple Sclerosis Controls +1 more

COMPLETED NA

Kappa Free Light Chains (KFLC) in Multiple Sclerosis (MS) and Clinically Isolated Syndrome (CIS)

NCT07183020

Multiple Sclerosis Clinically Isolated Syndrome (CIS)

ENROLLING_BY_INVITATION

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Sclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MS Patients

Blood sample

Intervention Type DIAGNOSTIC_TEST

2 x 4 ml tubes blood to screen for serum Neurofilament Light Chain and GFAP levels

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood sample

2 x 4 ml tubes blood to screen for serum Neurofilament Light Chain and GFAP levels

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The patient has been correctly informed.
* The patient must have given their informed and signed consent.
* The patient must be insured or beneficiary of a health insurance plan.
* The patient is at least (≥)15 years old.
* The patient has MS according to diagnosis criteria (Thompson et al. 2017) and:

* Participates to the OFSEP-HD cohort (ancillary study);
* Has a Expanded Disability Status Scale score comprised between 0 - 7.0;
* With or without Disease Modifying Drug;
* For Work Package 3: patients enrolled in any OFSEP-HD centre that meet landmark criteria for an active MS (relapse, or Expanded Disability Status Scale progression, or active MRI) during follow-up;
* For Work Package 4: patients with a stable disease enrolled in OFSEP-HD study in Nîmes or Nantes University Hospitals.

Exclusion Criteria

* Within the past three months, the patient has participated in another interventional study that may interfere with the results or conclusions of this study.
* The patient is in an exclusion period determined by a previous study.
* The patient is under judicial protection.
* The patient refuses to sign the consent.
* It is impossible to correctly inform the patient (inability to understand the study, language problem).
* The patient is pregnant or breast-feeding.
* The patient is under 15 years old.
* Inability to answer questionnaires.
* Clinically isolated syndrome (CIS) that does not meet the criteria of MS.
* Radiologically isolated syndrome (RIS).
* Patient with Neuromyelitis optica spectrum disorder.

Minimum Eligible Age

15 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Eric Thouvenot

Role: PRINCIPAL_INVESTIGATOR

CHU Nimes

Locations

Explore where the study is taking place and check the recruitment status at each participating site.